CalAmp has announced a strategic collaboration with Cryoport to develop a next generation condition monitoring system to further assure the security of global temperature controlled pharmaceutical shipments.
This research and development collaboration is aimed at enhancing the protection and preservation of critical life science shipments, which demonstrates CalAmp's continued momentum in the supply chain visibility market and Cryoport's commitment to providing the most advanced best-in-class, data-driven solutions to its biopharmaceutical client base.
It is estimated that pharmaceutical products that require temperature controlled storage and transport are worth approximately $283 billion, and they are expected to rise 70% between 2015 and 2021. Many drug companies are now moving into the large-molecule treatments, which require much more rigorous shipping solutions that meet exacting requirements. These medications are typically more temperature sensitive and have a shorter efficacy, resulting in the need for specialized handling and tracking.
Together with CalAmp, Cryoport is exploring an advanced supply chain visibility service that will monitor, in real-time, environmental readings for regenerative medicine product shipments using Bluetooth® sensor technology.
If successful, the combination of the Cryoport Express® Shippers and the Cryoportal® Logistics Management Platform, coupled with CalAmp's new-to-market SC iOn Tag™ Bluetooth sensor technology and SC iOn Command™ platform, would allow Cryoport to offer another advanced logistics solution that would pro-actively manage supply chain visibility across multi-mode global shipping routes.
"We are pleased with the relationship we are developing with CalAmp and the potential to provide advanced, next generation wireless, Bluetooth solutions that will track and report crucial information for life science shipments in ways that were heretofore not possible," said Jerrell Shelton, CEO of Cryoport. "We are entrusted with highly sensitive and valuable commodities, which require advanced technologies to provide safe and secure conditions at all times. Our Biopharma, Reproductive Medicine, and Animal Health markets require superior quality assurance and non-stop monitoring. The information we provide is vital when bringing biologics, regenerative medicine, vaccines, tissues and advanced therapies to market. The SaaS solutions we are working with CalAmp to develop should, if successful, enable us to add offerings that will significantly reduce the risks associated with the temperature-controlled transportation of commodities in our markets."
"We know how important it is to have access to accurate and sophisticated technology when handling temperature-sensitive commodities," said Jeff Newman, vice president of supply chain visibility solutions at CalAmp. "For supply chain and cold chain suppliers that are entrusted with these products, having real-time insight not only saves money, it also has the ability to save lives and advance the development of groundbreaking new cellular therapies. We are honored to have started this relationship with Cryoport."